CA2464322A1 - Methods of treatment using a gastric retained gabapentin dosage - Google Patents
Methods of treatment using a gastric retained gabapentin dosage Download PDFInfo
- Publication number
- CA2464322A1 CA2464322A1 CA002464322A CA2464322A CA2464322A1 CA 2464322 A1 CA2464322 A1 CA 2464322A1 CA 002464322 A CA002464322 A CA 002464322A CA 2464322 A CA2464322 A CA 2464322A CA 2464322 A1 CA2464322 A1 CA 2464322A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- gabapentin
- daily
- administered
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Abstract
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Claims (116)
1. A method of treating epilepsy comprising administering a therapeutically effective amount of gabapentin or a pharmaceutically acceptable salt thereof, in a gastric retained dosage form to a mammal in need of such treatment.
2. The method of Claim 1 wherein the dosage form is administered once-daily.
3. The method of Claim 2 wherein the dosage form is administered with a meal.
4. The method of Claim 1 wherein the dosage form is administered twice-daily.
5. The method of Claim 4 wherein each dosage form is administered with a meal.
6. The method of Claim 1 which further comprises administering one or more additional anti-epileptics or anticonvulsants.
7. The method of Claim 1 wherein the dosage form is administered once- or twice-daily and the total amount of gabapentin in the daily dosage is about 200-4000 mg.
8. The method of Claim 7 wherein the total amount of gabapentin in the daily dosage is about 600-2700 mg.
9. The method of Claim 8 wherein total amount of gabapentin in the daily dosage is about 900-1800 mg.
10. The method of Claim 1 wherein the dosage form is an extended release oral drug dosage form for releasing gabapentin into the stomach, duodenum and small intestine of the mammal.
11. The method of Claim 10 wherein gabapentin is administered from the dosage form for a period of at least 5 hours and at least 40wt% of the gabapentin is retained in the dosage form after 1 hour.
12. The method of Claim 11 wherein the dosage form provides administration of at least 80wt% of the gabapentin to be delivered over a period of about 5-12 hours.
13. The method of Claim 11 wherein the dosage form contains at least one hydrophilic polymer that swells to an extent such that it promotes gastric retention of the dosage form in the fed mode.
14. The method of Claim 13 wherein the polymer is selected from the group consisting of polyethylene oxides, alkyl substituted cellulose materials, and combinations thereof.
15. The method of Claim 11 wherein the dosage form further comprises a gas generating agent.
16. The method of Claim 15 wherein the gabapentin is contained in a membrane sachet with the gas generating agent.
17. The method of Claim 1 wherein the dosage form is an adhesive tablet.
18. The method of Claim 1 wherein the dosage form is a film coated dosage form or a capsule dosage form that allows for the extended release of gabapentin in the stomach duodenum and small intestine of the mammal.
19. The method of Claim 1 wherein the dosage form is a swellable, sustained-release tablet having a matrix comprised of polyethylene oxide) and hydroxypropylmethylcellulose.
20. A method of treating neuropathic pain comprising administering a therapeutically effective amount of gabapentin or a pharmaceutically acceptable salt thereof, in a gastric retained dosage form to a mammal in need of such treatment.
21. The method of Claim 20 wherein the dosage form is administered once-daily.
22. The method of Claim 21 wherein the dosage form is administered with a meal.
23. The method of Claim 20 wherein the dosage form is administered twice-daily.
24. The method of Claim 23 wherein each dosage form is administered with a meal.
25. The method of Claim 20 which further comprises administering one or more therapeutic agents selected from the group consisting of anticonvulsants, tricyclic antidepressants, opioids, and levodopa.
26. The method of Claim 20 wherein the dosage form is administered once- or twice-daily and the total amount of gabapentin in the daily dosage is about 100-4800 mg.
27. The method of Claim 26 wherein the total amount of gabapentin in the daily dosage is about 300-3600 mg.
28. The method of Claim 27 wherein the total amount of gabapentin in the daily dosage is about 900-2400 mg.
29. The method of Claim 20 wherein the dosage form is an extended release oral drug dosage form for releasing gabapentin into the stomach, duodenum and small intestine of the mammal.
30. The method of Claim 29 wherein gabapentin is administered from the dosage form for a period of at least 5 hours and at least 40wt% of the gabapentin is retained in the dosage form after 1 hour.
31. The method of Claim 30 wherein the dosage form provides administration of at least 85wt% of the gabapentin to be delivered over a period of about 5-12 hours.
32. The method of Claim 30 wherein the dosage form contains at least one hydrophilic polymer that swells to an extent such that it promotes gastric retention of the dosage form in the fed mode.
33. The method of Claim 32 wherein the polymer is selected from the group consisting of polyethylene oxides, alkyl substituted cellulose materials, and combinations thereof.
34. The method of Claim 30 wherein the dosage form further comprises a gas generating agent.
35. The method of Claim 34 wherein the gabapentin is contained in a membrane sachet with the gas generating agent.
36. The method of Claim 20 wherein the dosage form is an adhesive tablet.
37. The method of Claim 20 wherein the dosage form is a film coated dosage form or a capsule dosage form that allows for the extended release of gabapentin in the stomach duodenum and small intestine of the mammal.
38. The method of Claim 20 wherein the dosage form is a swellable, sustained-release tablet having a matrix comprised of poly(ethylene oxide) and hydroxypropylmethylcellulose.
39. A method of treating psychiatric disorders comprising administering a therapeutically effective amount of gabapentin or a pharmaceutically acceptable salt thereof, in a gastric retained dosage form to a mammal in need of such treatment.
40. The method of Claim 39 wherein the psychiatric disorder is bipolar disorder or panic disorder.
41. The method of Claim 39 wherein the dosage form is administered once-daily.
42. The method of Claim 41 wherein the dosage form is administered with a meal.
43. The method of Claim 39 wherein the dosage form is administered twice-daily.
44. The method of Claim 43 wherein each dosage form is administered with a meal.
45. The method of Claim 39 which further comprises administering one or more therapeutic agents selected from the group consisting of anticonvulsants, tricyclic antidepressants, opioids, and levodopa.
46. The method of Claim 39 wherein the dosage form is administered once- or twice-daily and the total amount of gabapentin in the daily dosage is about 100-4800 mg.
47. The method of Claim 46 wherein the total amount of gabapentin in the daily dosage is about 900-3600 mg.
48. The method of Claim 39 wherein the dosage form is an extended release oral drug dosage form for releasing gabapentin into the stomach, duodenum and small intestine of the mammal.
49. The method of Claim 48 wherein gabapentin is administered from the dosage form for a period of at least 5 hours and at least 40wt% of the gabapentin is retained in the dosage form after 1 hour.
50. The method of Claim 49 wherein the dosage form provides administration of at least 85wt% of the gabapentin to be delivered over a period of about 5-12 hours.
51. The method of Claim 49 wherein the dosage form contains at least one hydrophilic polymer that swells to an extent such that it promotes gastric retention of the dosage form in the fed mode.
52. The method of Claim 51 wherein the polymer is selected from the group consisting of polyethylene oxides, alkyl substituted cellulose materials, and combinations thereof.
53. The method of Claim 49 wherein the dosage form further comprises a gas generating agent.
54. The method of Claim 53 wherein the gabapentin is contained in a membrane sachet with the gas generating agent.
55. The method of Claim 39 wherein the dosage form is an adhesive tablet.
56. The method of Claim 39 wherein the dosage form is a film coated dosage form or a capsule dosage form that allows for the extended release of gabapentin in the stomach.
57. The method of Claim 39 wherein the dosage form is a swellable, sustained-release tablet having a matrix comprised of polyethylene oxide) and hydroxypropylmethylcellulose.
58. A method of treating movement disorders comprising administering a therapeutically effective amount of gabapentin or a pharmaceutically acceptable salt thereof, in a gastric retained dosage form to a mammal in need of such treatment.
59. The method of Claim 58 wherein the movement disorder is restless leg syndrome, periodic movement disorder of sleep, essential tremor or acquired nystagmus.
60. The method of Claim 58 wherein the dosage form is administered once-daily.
61. The method of Claim 60 wherein the dosage form is administered with a meal.
62. The method of Claim 58 wherein the dosage form is administered twice-daily.
63. The method of Claim 62 wherein each dosage form is administered with a meal.
64. The method of Claim 58 which further comprises administering one or more therapeutic agents selected from the group consisting of anticonvulsants, tricyclic antidepressants, opioids, benzodiazepine, and dopaminergic agents.
65. The method of Claim 58 wherein the dosage form is administered once- or twice-daily and the total amount of gabapentin in the daily dosage is about 100-4000 mg.
66. The method of Claim 65 wherein the total amount of gabapentin in the daily dosage is about 200-3000 mg.
67. The method of Claim 66 wherein the total amount of gabapentin in the daily dosage is about 500-2700 mg.
68. The method of Claim 58 wherein the dosage form is an extended release oral drug dosage form for releasing gabapentin into the stomach, duodenum and small intestine of the mammal.
69. The method of Claim 68 wherein gabapentin is administered from the dosage form for a period of at least 5 hours and at least 40wt% of the gabapentin is retained in the dosage form after 1 hour.
70. The method of Claim 69 wherein the dosage form provides administration of at least 80wt% of the gabapentin to be delivered over a period of about 5-12 hours.
71. The method of Claim 69 wherein the dosage form contains a hydrophilic polymer that swells to a size such that the dosage form is retained in the fed mode.
72. The method of Claim 71 wherein the polymer is selected from the group consisting of polyethylene oxides, alkyl substituted cellulose materials, and combinations thereof.
73. The method of Claim 69 wherein the dosage form further comprises a gas generating agent.
74. The method of Claim 73 wherein the gabapentin is contained in a membrane sachet with the gas generating agent.
75. The method of Claim 58 wherein the dosage form is an adhesive tablet.
76. The method of Claim 58 wherein the dosage form is a film coated dosage form or a capsule dosage form that allows for the extended release of gabapentin in the stomach.
77. The method of Claim 58 wherein the dosage form is a swellable, sustained-release tablet having a matrix comprised of poly(ethylene oxide) and hydroxypropylmethylcellulose.
78. A method for the prophylactic treatment of migraine headaches comprising administering a therapeutically effective amount of gabapentin or a pharmaceutically acceptable salt thereof, in a gastric retained dosage form to a mammal in need of such treatment.
79. The method of Claim 78 wherein the dosage form is administered once-daily.
80. The method of Claim 79 wherein the dosage form is administered with a meal.
81. The method of Claim 78 wherein the dosage form is administered twice-daily.
82. The method of Claim 81 wherein each dosage form is administered with a meal.
83. The method of Claim 78 which further comprises administering one or more therapeutic agents selected from the group consisting of anticonvulsants, tricyclic antidepressants, opioids, and levodopa.
84. The method of Claim 78 wherein the dosage form is administered once- or twice-daily and the total amount of gabapentin in the daily dosage is about 200-4000 mg.
85. The method of Claim 84 wherein the total amount of gabapentin in the daily dosage is about 500-3600 mg.
86. The method of Claim 85 wherein the total amount of gabapentin in the daily dosage is about 900-2400 mg.
87. The method of Claim 78 wherein the dosage form is an extended release oral drug dosage form for releasing gabapentin into the stomach, duodenum and small intestine of the mammal.
88. The method of Claim 87 wherein gabapentin is administered from the dosage form for a period of at least 5 hours and at least 40wt% of the gabapentin is retained in the dosage form after 1 hour.
89. The method of Claim 88 wherein the dosage form provides administration of at least 85wt% of the gabapentin to be delivered over a period of about 5-12 hours.
90. The method of Claim 88 wherein the dosage form contains at least one hydrophilic polymer that swells to an extent such that it promotes gastric retention of the dosage form in the fed mode.
91. The method of Claim 90 wherein the polymer is selected from the group consisting of polyethylene oxides, alkyl substituted cellulose materials, and combinations thereof.
92. The method of Claim 88 wherein the dosage form further comprises a gas generating agent.
93. The method of Claim 92 wherein the gabapentin is contained in a membrane sachet with the gas generating agent.
94. The method of Claim 78 wherein the dosage form is an adhesive tablet.
95. The method of Claim 78 wherein the dosage form is a film coated dosage form or a capsule dosage form that allows for the extended release of gabapentin in the stomach duodenum and small intestine of the mammal.
96. The method of Claim 78 wherein the dosage form is a swellable, sustained-release tablet having a matrix comprised of poly(ethylene oxide) and hydroxypropylmethylcellulose.
97. An improved method of administering a therapeutically effective amount of gabapentin to a patient in need thereof, the improvement comprising administering gabapentin or a pharmaceutically acceptable salt thereof, in a gastric retained dosage form.
98. The method of Claim 97 wherein the dosage form is administered once-daily.
99. The method of Claim 98 wherein the dosage form is administered with a meal.
100. The method of Claim 97 wherein the dosage form is administered twice-daily.
101. The method of Claim 100 wherein each dosage form is administered with a meal.
102. The method of Claim 97 where the patient is being treated for epilepsy.
103. The method of Claim 97 where the patient is being treated for neuropathic pain.
104. The method of Claim 97 where the patient is being treated for psychiatric disorders.
105. The method of Claim 97 where the patient is being treated for movement disorders.
106. The method of Claim 97 where the patient is receiving prophylactic treatment for migraine headaches.
107. The method of Claim 97 wherein the dosage form is an extended release oral drug dosage form for releasing gabapentin into the stomach, duodenum and small intestine of the mammal.
108. The method of Claim 107 wherein gabapentin is administered from the dosage form for a period of at least 5 hours and at least 40wt% of the gabapentin is retained in the dosage form after 1 hour.
109. The method of Claim 108 wherein the dosage form provides administration of at least 80wt% of the gabapentin to be delivered over a period of about 5-12 hours.
110. The method of Claim 108 wherein the dosage form contains at least one hydrophilic polymer that swells to an extent such that it promotes gastric retention of the dosage form in the fed mode.
111. The method of Claim 110 wherein the polymer is selected from the group consisting of polyethylene oxides, alkyl substituted cellulose materials, and combinations thereof.
112. The method of Claim 108 wherein the dosage form further comprises a gas generating agent.
113. The method of Claim 112 wherein the gabapentin is contained in a membrane sachet with the gas generating agent.
114. The method of Claim 97 wherein the dosage form is an adhesive tablet.
115. The method of Claim 97 wherein the dosage form is a film coated dosage form or a capsule dosage form that allows for the extended release of gabapentin in the stomach.
116. The method of Claim 97 wherein the dosage form is a swellable, sustained-release tablet having a matrix comprised of poly(ethylene oxide) and hydroxypropyl methylcellulose.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33524801P | 2001-10-25 | 2001-10-25 | |
US60/335,248 | 2001-10-25 | ||
PCT/IB2002/005440 WO2003035040A1 (en) | 2001-10-25 | 2002-10-25 | Methods of treatment using a gastric retained gabapentin dosage |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2464322A1 true CA2464322A1 (en) | 2003-05-01 |
CA2464322C CA2464322C (en) | 2011-10-11 |
Family
ID=23310919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2464322A Expired - Lifetime CA2464322C (en) | 2001-10-25 | 2002-10-25 | Methods of treatment using a gastric retained gabapentin dosage |
Country Status (9)
Country | Link |
---|---|
US (10) | US7438927B2 (en) |
EP (2) | EP1439825B2 (en) |
JP (2) | JP5421511B2 (en) |
AU (1) | AU2002348828B2 (en) |
CA (1) | CA2464322C (en) |
DK (1) | DK1439825T4 (en) |
MX (1) | MXPA04003946A (en) |
TW (1) | TWI312285B (en) |
WO (1) | WO2003035040A1 (en) |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056531B1 (en) * | 2000-05-04 | 2006-06-06 | Nature's Way Products, Inc. | Sustained release compositions for orally administered substances and methods |
US6833140B2 (en) * | 2001-06-11 | 2004-12-21 | Xenoport, Inc. | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
EP1513504A1 (en) * | 2002-06-07 | 2005-03-16 | Ranbaxy Laboratories, Ltd. | Sustained release oral dosage forms of gabapentin |
US7939102B2 (en) * | 2002-06-07 | 2011-05-10 | Torrent Pharmaceuticals Ltd. | Controlled release formulation of lamotrigine |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20040147509A1 (en) | 2003-01-13 | 2004-07-29 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
WO2005009432A1 (en) * | 2003-07-29 | 2005-02-03 | Ranbaxy Laboratories Limited | New dosage regimen in case of concurrent intake of gabapentin with food and an increased oral bioavailability therewith |
DE10361596A1 (en) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102004020220A1 (en) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE102005005446A1 (en) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE102004032051A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE502004004205D1 (en) * | 2003-08-06 | 2007-08-09 | Gruenenthal Gmbh | AGAINST MISUSE SECURED PHARMACEUTICAL FORM |
US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
ITMI20032399A1 (en) * | 2003-12-09 | 2005-06-10 | Zambon Spa | PHARMACEUTICAL COMPOSITION CONTAINING GABAPENTIN. |
WO2005077332A2 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof |
GB0405200D0 (en) * | 2004-03-08 | 2004-04-21 | Pfizer Ltd | Combinations comprising alpha-2-delta ligands |
GB0408308D0 (en) * | 2004-04-14 | 2004-05-19 | Vectura Ltd | Pharmaceutical compositions |
US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
MX2007002790A (en) * | 2004-09-07 | 2007-04-23 | Pfizer | Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine. |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
CA2580329C (en) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
CN101068538A (en) | 2004-11-04 | 2007-11-07 | 什诺波特有限公司 | Gaba analog prodrug sustained release oral dosage forms |
DE102005005449A1 (en) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
JP2008536928A (en) * | 2005-04-19 | 2008-09-11 | アルザ・コーポレーシヨン | A combination of tramadol and a substance comprising gabapentin |
PL1919466T3 (en) | 2005-07-11 | 2012-05-31 | Cortria Corp | Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative |
US20070092565A1 (en) * | 2005-10-25 | 2007-04-26 | Pharmascience Inc. | Gastric retention drug delivery system |
NL2000281C2 (en) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Solid pharmaceutical compositions containing pregabalin. |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
AU2006332690A1 (en) * | 2005-12-29 | 2007-07-12 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
DE102007011485A1 (en) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
CA2682661C (en) | 2007-03-22 | 2017-03-14 | Dendreon Corporation | Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity |
EP2249811A1 (en) * | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
US8329750B2 (en) | 2008-02-11 | 2012-12-11 | Depomed, Inc. | Methods for treating vasomotor symptoms using GABA analogs in a gastric retentive dosage form |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
WO2009114648A1 (en) | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
HUE030803T2 (en) * | 2008-05-09 | 2017-06-28 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
JP2010043063A (en) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | Diagnosis and treatment of kawasaki disease |
WO2010019915A1 (en) * | 2008-08-15 | 2010-02-18 | Depomed Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders |
EP3195896A1 (en) | 2009-05-05 | 2017-07-26 | Board of Regents, The University of Texas System | Novel formulations of volatile anesthetics and methods of use for reducing inflammation |
PE20120572A1 (en) * | 2009-07-22 | 2012-06-06 | Gruenenthal Chemie | HANDLING RESISTANT STABILIZED OXIDATION DOSAGE FORM |
EP2456427B1 (en) | 2009-07-22 | 2015-03-04 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
US8242141B2 (en) * | 2009-09-16 | 2012-08-14 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
US20110135728A1 (en) * | 2009-12-08 | 2011-06-09 | Miller Jennifer L | Gastric retentive pharmaceutical compositions for extended release of polypeptides |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
CA2832436C (en) * | 2010-04-07 | 2018-08-14 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
WO2011151708A1 (en) | 2010-06-01 | 2011-12-08 | Rubicon Research Private Limited | Gastroretentive dosage forms of gaba analogs |
US20120009261A1 (en) * | 2010-07-06 | 2012-01-12 | Grünenthal GmbH | Novel gastro-retentive dosage forms |
AU2011289407B2 (en) | 2010-08-11 | 2015-06-18 | Philadelphia Health & Education Corporation | Novel D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease |
NZ607392A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising inorganic salt |
PE20131126A1 (en) | 2010-09-02 | 2013-10-21 | Gruenenthal Chemie | ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER |
US8435993B2 (en) | 2010-12-07 | 2013-05-07 | Philadelphia Health And Education Corporation | Methods of inhibiting metastasis from cancer |
US8476221B2 (en) | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
EP2736495B1 (en) | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
DK2736497T3 (en) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Shock-resistant tablet that provides an immediate release of a drug. |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
KR101939710B1 (en) | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | Hepatitis b antiviral agents |
MX356421B (en) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer. |
LT2838512T (en) | 2012-04-18 | 2018-11-12 | GrĆ¼nenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
EP2874997A4 (en) | 2012-07-19 | 2016-01-06 | Univ Drexel | Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
EP3158995B1 (en) | 2012-08-09 | 2018-05-23 | Dynamis Therapeutics, Inc. | Meglumine for reducing high triglyceride levels |
EP2698144A1 (en) | 2012-08-12 | 2014-02-19 | Ali Raif Ilaç Sanayi ve Ticaret Anonim Sirketi | Prolonged release gabapentin tablet formulation whose ability to stay in the stomach is improved |
EP2941233B1 (en) | 2013-01-07 | 2020-10-07 | The Trustees of the University of Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma |
MX2015016254A (en) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Tamper resistant dosage form with bimodal release profile. |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US10166207B2 (en) | 2013-06-05 | 2019-01-01 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
AU2014284267B2 (en) | 2013-07-02 | 2018-05-10 | Ecoplanet Environmental Llc | Volatile organic compound formulations having antimicrobial activity |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
EP3074049B1 (en) | 2013-11-26 | 2020-05-06 | Yale University | Novel cell-penetrating compositions and methods using same |
EP3079692A4 (en) | 2013-12-09 | 2017-10-18 | Thomas Jefferson University | Novel methods of treating a neurodegenerative disease in a mammal in need thereof |
CA2982270C (en) | 2014-04-07 | 2023-01-10 | Women & Infants Hospital Of Rhode Island | Novel 7-dehydrocholesterol derivatives and methods using same |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
CA2968215A1 (en) | 2014-08-20 | 2016-02-25 | Yale University | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss |
AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
JP2018511127A (en) | 2015-03-12 | 2018-04-19 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Craving input and support system |
WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
WO2016182968A1 (en) | 2015-05-08 | 2016-11-17 | Brown University | Novel syringolin analogues and methods of making and using same |
AU2016264364B2 (en) | 2015-05-19 | 2022-06-23 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
KR102207539B1 (en) | 2015-06-30 | 2021-01-26 | 네우라드 리미티드 | Novel respiratory control modulating compounds, and methods of making and using the same |
WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3368505B1 (en) | 2015-10-28 | 2023-02-22 | Yale University | Quinoline amides and methods of using same |
CA3005142A1 (en) | 2015-11-20 | 2017-05-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
US10143687B2 (en) | 2016-04-11 | 2018-12-04 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US10292977B2 (en) | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US20190119364A1 (en) | 2016-04-29 | 2019-04-25 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and compositions useful for treating metabolic syndrome, and methods using same |
BR112019000636A2 (en) | 2016-07-17 | 2019-04-30 | Mapi Pharma Ltd. | Pregabalin prolonged release dosage forms |
WO2018026764A1 (en) | 2016-08-01 | 2018-02-08 | University Of Rochester | Nanoparticles for controlled release of anti-biofilm agents and methods of use |
WO2018027024A1 (en) | 2016-08-05 | 2018-02-08 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
CN109843379B (en) | 2016-09-01 | 2022-12-30 | 梅比斯发现公司 | Substituted ureas and methods of making and using the same |
CA3040919A1 (en) | 2016-11-07 | 2018-05-11 | Arbutus Biopharma Corporation | Substituted pyridinone-containing tricyclic compounds, and methods using same |
JP2020503950A (en) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Device and method for transdermal drug delivery |
EP4219486A1 (en) | 2017-01-19 | 2023-08-02 | Temple University of the Commonwealth System of Higher Education | Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use |
US11098010B2 (en) | 2017-03-21 | 2021-08-24 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
EP3612184A4 (en) | 2017-04-17 | 2021-01-20 | Yale University | Compounds, compositions and methods of treating or preventing acute lung injury |
EP3659307A4 (en) | 2017-07-28 | 2021-09-22 | Yale University | Anticancer Drugs and Methods of Making and Using Same |
CA3074017A1 (en) | 2017-09-08 | 2019-03-14 | The Regents Of The University Of Colorado, A Body Corporate | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers |
WO2019104316A1 (en) | 2017-11-27 | 2019-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds, compositions, and methods for treating and/or preventing periodontal disease |
WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
US11325920B2 (en) | 2018-01-24 | 2022-05-10 | The Rockefeller University | Antibacterial compounds, compositions thereof, and methods using same |
KR20200116110A (en) | 2018-01-29 | 2020-10-08 | 듀크 유니버시티 | Composition and method for increasing 5-hydroxytryptophan bioavailability |
CN112204025B (en) | 2018-05-29 | 2022-05-31 | 瑟赛治疗公司 | Compounds for the treatment of pain, compositions comprising the same and methods of using the same |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
CA3103477A1 (en) | 2018-06-19 | 2019-12-26 | National University Of Singapore | Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications |
CN112839661A (en) | 2018-10-11 | 2021-05-25 | 萨尼菲特治疗有限公司 | Inositol phosphates for the treatment of ectopic calcification |
TWI827760B (en) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same |
CN113365636A (en) | 2019-01-30 | 2021-09-07 | 萨尼菲特治疗有限公司 | Phosphoinositide compounds for increasing tissue perfusion |
US20200246317A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent |
WO2020159565A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent |
US11524048B2 (en) | 2019-05-09 | 2022-12-13 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of severe sepsis |
US11555010B2 (en) | 2019-07-25 | 2023-01-17 | Brown University | Diamide antimicrobial agents |
EP3818983A1 (en) | 2019-11-11 | 2021-05-12 | Sanifit Therapeutics S.A. | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
IL298853A (en) | 2020-06-09 | 2023-02-01 | Inozyme Pharma Inc | Soluble enpp1 or enpp3 proteins and uses thereof |
EP4015494A1 (en) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Processes for the preparation of soluble salts of inositol phosphates |
EP4036097A1 (en) | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
CA3226223A1 (en) | 2021-07-30 | 2023-02-02 | Jacob Pade Ramsoe Jacobsen | 5-hydroxytryptophan gastroretentive dosage forms |
US11779567B2 (en) | 2021-10-14 | 2023-10-10 | Evecxia Therapeutics, Inc. | Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes |
WO2024023359A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
WO2024023360A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip5 substituted compounds |
WO2024052895A1 (en) | 2022-09-06 | 2024-03-14 | Hadasit Medical Research Services And Development Ltd | Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US43946A (en) * | 1864-08-23 | Improvement in hay-elevating forks | ||
US12679A (en) * | 1855-04-10 | phdto-litho | ||
US3574820A (en) | 1968-01-08 | 1971-04-13 | Upjohn Co | Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
DE2460891C2 (en) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds |
US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
US3977404A (en) | 1975-09-08 | 1976-08-31 | Alza Corporation | Osmotic device having microporous reservoir |
DE2611690A1 (en) | 1976-03-19 | 1977-09-22 | Goedecke Ag | CYCLIC SULFONYLOXYIMIDE |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4309406A (en) | 1979-07-10 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4462839A (en) | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
US4851232A (en) | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
US4894476A (en) | 1988-05-02 | 1990-01-16 | Warner-Lambert Company | Gabapentin monohydrate and a process for producing the same |
US5002772A (en) | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
DE3928183A1 (en) | 1989-08-25 | 1991-02-28 | Goedecke Ag | LACTAM-FREE CYCLIC AMINO ACIDS |
US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
EP0458751A1 (en) | 1990-05-25 | 1991-11-27 | Warner-Lambert Company | Delivery system for cyclic amino acids with improved taste, texture and compressibility |
IT1250483B (en) | 1990-08-30 | 1995-04-07 | Eurand Int | MULTIPLE DIE DELAY SYSTEM |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US5232704A (en) | 1990-12-19 | 1993-08-03 | G. D. Searle & Co. | Sustained release, bilayer buoyant dosage form |
US5273758A (en) | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
ES2124303T3 (en) | 1992-03-25 | 1999-02-01 | Depomed Inc | DOSAGE FORMS OF DELAYED DELIVERY ORAL DRUGS BASED ON HYDROXYETHYL CELLULOSE. |
US5382435A (en) | 1993-03-24 | 1995-01-17 | Southwest Research Institute | Microparticulate pharmaceutical delivery system |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
DE4406424A1 (en) | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandable dosage forms |
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
HU220959B1 (en) | 1994-04-29 | 2002-07-29 | Mcneil-Ppc Inc. | Layered absorbent products and method for preparation of it |
SI9520049A (en) | 1994-05-06 | 1997-12-31 | Pfizer | Controlled-release dosage forms of azithromycin |
DE4432757A1 (en) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmaceutical preparation containing metformin and process for its preparation |
MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
ATE214596T1 (en) | 1995-04-14 | 2002-04-15 | Pharma Pass | SOLID COMPOSITIONS CONTAINING A NON-AMORPHOUS ACTIVE SUBSTANCE AND POLYETHYLENE OXIDE |
US6117453A (en) | 1995-04-14 | 2000-09-12 | Pharma Pass | Solid compositions containing polyethylene oxide and an active ingredient |
US5558879A (en) | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
US5783212A (en) * | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
WO1997047285A1 (en) | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
WO1998007447A1 (en) * | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US6255526B1 (en) | 1996-12-24 | 2001-07-03 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin |
US5872984A (en) | 1997-04-01 | 1999-02-16 | International Business Machines Corporation | Uninterruptible power supply providing continuous power mainstore function for a computer system |
US20010046473A1 (en) * | 1997-04-18 | 2001-11-29 | Jerome Besse | Gastric-retained pharmaceutical composition and method for its use |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
ES2248908T7 (en) * | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Dosage forms of drugs orally and gastric retention for continued release of highly soluble drugs |
US20010004644A1 (en) * | 1997-07-21 | 2001-06-21 | Levin Bruce H. | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation |
US6432986B2 (en) * | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
US6110499A (en) * | 1997-07-24 | 2000-08-29 | Alza Corporation | Phenytoin therapy |
ES2234139T3 (en) | 1997-08-11 | 2005-06-16 | Alza Corporation | DOSAGE FORM OF AN ACTIVE PROLONGED RELEASE AGENT ADAPTED FOR GASTRIC RETENTION. |
AU8668598A (en) * | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
BR9812162A (en) | 1997-09-08 | 2000-07-18 | Warner Lambert Co | Analgesic compositions comprising antiepileptic compounds and methods for using them |
FR2769107B1 (en) | 1997-09-30 | 2001-07-13 | Centre Nat Rech Scient | CODING METHOD, EQUIPMENT FOR CODING AND PRODUCT THUS ENCODED |
US6294690B1 (en) | 1997-10-07 | 2001-09-25 | Warner-Lambert Company | Process for preparing a cyclic amino acid anticonvulsant compound |
CA2220038A1 (en) | 1998-01-05 | 1999-07-05 | Amina Odidi | Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances |
ID26082A (en) | 1998-03-19 | 2000-11-23 | Briston Myers Squib Company | DWIFASA CONTROLLED REMOVAL DELIVERY SYSTEM FOR HIGH SOLUTION PHARMACY SUBSTANCES AND ITS METHODS |
US20040062802A1 (en) | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
FR2781793B1 (en) | 1998-08-03 | 2001-07-20 | Prographarm Lab | PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES |
AU9266098A (en) | 1998-09-03 | 2000-03-27 | Stefan Kraft | Anti-abrasion device mainly for protecting edges against abrasion |
US7214711B2 (en) * | 1998-12-23 | 2007-05-08 | Neurotherapeutics Pharma Llc | Method of treating migraine headache without aura |
US6635281B2 (en) * | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
AU3216600A (en) | 1999-03-10 | 2000-09-28 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
ES2255490T3 (en) * | 1999-03-31 | 2006-07-01 | Janssen Pharmaceutica N.V. | PREGELATINIZED ALMIDON IN A CONTROLLED RELEASE FORMULATION. |
US6162466A (en) | 1999-04-15 | 2000-12-19 | Taro Pharmaceutical Industries Ltd. | Sustained release formulation of carbamazepine |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
AU5680100A (en) * | 1999-06-14 | 2001-01-02 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
CA2378918C (en) | 1999-07-22 | 2007-01-23 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes |
US6294198B1 (en) * | 1999-08-24 | 2001-09-25 | Purepac Pharmaceutical Co. | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same |
AU781718B2 (en) | 1999-11-02 | 2005-06-09 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
EP1118321A1 (en) * | 2000-01-14 | 2001-07-25 | Ucb, S.A. | Solid pharmaceutical compositions for the controlled delivery of active substances |
ES2270982T3 (en) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | DOSAGE FORM OF NUCLEO AND CARCASA THAT IS APPROXIMATE TO A RELEASE OF THE ZERO ORDER PHARMACO. |
US6333352B1 (en) * | 2000-04-05 | 2001-12-25 | Mimicking Man Manually, Inc. | Method of treating benign positional vertigo |
US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
WO2001076478A1 (en) | 2000-04-10 | 2001-10-18 | Nordisk Terapi As | System for testing and exercising sensorimotoric control of the neck |
US6350471B1 (en) | 2000-05-31 | 2002-02-26 | Pharma Pass Llc | Tablet comprising a delayed release coating |
KR100667721B1 (en) | 2000-06-16 | 2007-01-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | Stable gabapentin having ph within a controlled range |
ES2193008T3 (en) | 2000-06-16 | 2004-07-01 | Teva Pharmaceutical Industries Ltd. | STABLE GABAPENTINA CONTAINING MORE THAN 20 PPM CHLORINE IONS. |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
US6683112B2 (en) | 2000-10-24 | 2004-01-27 | Andrx Corporation | Gabapentin prodrugs and formulations |
MX229421B (en) | 2001-02-27 | 2005-07-25 | Coating and binding agent for pharmaceutical formulations with improved storage stability. | |
US20030031711A1 (en) | 2001-05-29 | 2003-02-13 | Fara John W. | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
EP1412324A4 (en) * | 2001-06-11 | 2004-09-29 | Xenoport Inc | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
ITMI20011338A1 (en) | 2001-06-26 | 2002-12-26 | Farmatron Ltd | ORAL PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE OF THE ACTIVE INGREDIENT |
ITMI20011337A1 (en) * | 2001-06-26 | 2002-12-26 | Farmatron Ltd | ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF THE ACTIVE SUBSTANCE |
CA2452738C (en) * | 2001-07-04 | 2011-06-14 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US20030104052A1 (en) | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030152622A1 (en) | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US20070184104A1 (en) | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US20060159743A1 (en) | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
WO2003061656A1 (en) * | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
EP1513504A1 (en) * | 2002-06-07 | 2005-03-16 | Ranbaxy Laboratories, Ltd. | Sustained release oral dosage forms of gabapentin |
AU2003261147A1 (en) | 2002-07-12 | 2004-02-02 | University Of Rochester | Use of amino acids for treatment of various conditions |
WO2004084880A1 (en) | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
WO2006053186A2 (en) * | 2004-11-10 | 2006-05-18 | The Trustees Of Columbia University In The City Of New York | Method for treatment of movement disorders |
US20070148238A1 (en) * | 2005-06-23 | 2007-06-28 | Spherics, Inc. | Dosage forms for movement disorder treatment |
US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
BRPI0720252A2 (en) * | 2006-12-08 | 2014-01-07 | Xenoport Inc | Use of GABA ANALOG PRODUCTS TO TREAT DISEASES |
US20080226715A1 (en) * | 2007-03-16 | 2008-09-18 | Albert Cha | Therapeutic compositions and methods |
CA2706596A1 (en) * | 2007-11-23 | 2009-05-28 | Protect Pharmaceutical Corporation | Tapentadol compositions |
EP2240022B1 (en) * | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
CA2732131A1 (en) * | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
ES2719900T3 (en) * | 2008-09-05 | 2019-07-16 | Gruenenthal Gmbh | Pharmaceutical combination of 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and pregabalin or gabapentin |
US20100190752A1 (en) * | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
US20110268666A1 (en) * | 2008-09-29 | 2011-11-03 | Yissum Research Development Company of the Research University of Jerusalem, Ltd. | Novel gastroretentive delivery system |
CN102341098A (en) * | 2009-03-06 | 2012-02-01 | 什诺波特有限公司 | Oral dosage forms having high loading of gabapentin prodrug |
US20110053914A1 (en) * | 2009-08-28 | 2011-03-03 | Gruenenthal Gmbh | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic |
-
2002
- 2002-10-24 TW TW091124777A patent/TWI312285B/en not_active IP Right Cessation
- 2002-10-25 DK DK02781665.1T patent/DK1439825T4/en active
- 2002-10-25 EP EP02781665.1A patent/EP1439825B2/en not_active Expired - Lifetime
- 2002-10-25 CA CA2464322A patent/CA2464322C/en not_active Expired - Lifetime
- 2002-10-25 MX MXPA04003946A patent/MXPA04003946A/en active IP Right Grant
- 2002-10-25 AU AU2002348828A patent/AU2002348828B2/en not_active Ceased
- 2002-10-25 JP JP2003537607A patent/JP5421511B2/en not_active Expired - Fee Related
- 2002-10-25 EP EP10179051A patent/EP2266539A3/en not_active Withdrawn
- 2002-10-25 WO PCT/IB2002/005440 patent/WO2003035040A1/en active Application Filing
-
2003
- 2003-01-22 US US10/280,309 patent/US7438927B2/en not_active Expired - Lifetime
-
2008
- 2008-09-26 US US12/239,591 patent/US7731989B2/en not_active Expired - Fee Related
-
2010
- 2010-03-29 US US12/749,101 patent/US8252332B2/en not_active Expired - Lifetime
- 2010-08-09 JP JP2010179064A patent/JP2010254713A/en active Pending
-
2011
- 2011-05-19 US US13/111,575 patent/US8192756B2/en not_active Expired - Lifetime
- 2011-11-21 US US13/301,644 patent/US8231905B2/en not_active Expired - Lifetime
-
2012
- 2012-02-14 US US13/396,441 patent/US8409613B2/en not_active Expired - Fee Related
- 2012-07-19 US US13/553,622 patent/US8333991B2/en not_active Expired - Lifetime
- 2012-07-27 US US13/560,938 patent/US8333992B2/en not_active Expired - Lifetime
-
2013
- 2013-04-01 US US13/854,433 patent/US8580303B2/en not_active Expired - Fee Related
- 2013-11-08 US US14/075,965 patent/US20140072623A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2464322A1 (en) | Methods of treatment using a gastric retained gabapentin dosage | |
US6417184B1 (en) | Triple drug therapy for the treatment and prevention of acute or chronic pain | |
JP2918331B2 (en) | Pharmaceutical mixtures and devices for using them | |
AU2002303897B2 (en) | System for osmotic delivery of pharmaceutically active agents | |
JP2005507400A5 (en) | ||
JP2005508358A5 (en) | ||
AU2002348828A1 (en) | Methods of treatment using a gastric retained gabapentin dosage | |
JP2005506367A5 (en) | ||
EP0397831A1 (en) | Treatment of obesity. | |
JPH03170421A (en) | Method and composition for diminishing appetite | |
CA2601289A1 (en) | Once-a-day oxycodone formulations | |
AU6836500A (en) | Drug therapy of the restless leg syndrome | |
JPH059412B2 (en) | ||
TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
RU2006139819A (en) | APPLICATION OF SYMETICON FOR PATIENTS POSITIONED FOR CONSTIPATION | |
EP1496868A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
KR20090125748A (en) | Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia | |
KR101231542B1 (en) | Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland disease | |
JP2000500159A (en) | Painkillers combined with melatonin | |
GB2321190A (en) | Medicament pack for treating Parkinson's Disease | |
WO2005009432A1 (en) | New dosage regimen in case of concurrent intake of gabapentin with food and an increased oral bioavailability therewith | |
MD1469G2 (en) | Method of treatment of the burn shock |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20221025 |